CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Capex Y/Y Annual
X4 Pharmaceuticals Inc  (NASDAQ: XFOR)
Other Ticker:  
 
 

XFOR's Capital Expenditures Growth by Quarter and Year

X4 Pharmaceuticals Inc's Capital Expenditures results by quarter and year

 



XFOR Capital Expenditures (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December - 7.04 0.01 0.01
3rd Quarter September - 0.09 0.01 0.04
2nd Quarter June - 0.13 0.00 0.02
1st Quarter March 0.00 0.06 0.03 0.01
FY   0.00 7.32 0.05 0.08

XFORs Annual Capital Expenditures
X4 Pharmaceuticals Inc's Capital Expenditures in the fiscal year 2024 $ 7.33 millions
X4 Pharmaceuticals Inc's Capital Expenditures in the fiscal year 2022 $ 0.10 millions
X4 Pharmaceuticals Inc's Capital Expenditures in the fiscal year 2021 $ 0.62 millions
X4 Pharmaceuticals Inc's Capital Expenditures in the fiscal year 2020 $ 1.36 millions
X4 Pharmaceuticals Inc's Capital Expenditures in the fiscal year 2019 $ 0.17 millions




XFOR Capital Expenditures first quarter 2025 Y/Y Growth Comment
X4 Pharmaceuticals Inc in the first quarter 2025 recorded Capital Expenditures of $ 0.00 millions.

Looking into first quarter 2025 results within Biotechnology & Pharmaceuticals industry 6 other companies have achieved higher Capital Expenditures growth. While X4 Pharmaceuticals Inc' s Capital Expenditures meltdown of -100% ranks overall at the positon no. 387 in the first quarter 2025.


XFOR Capital Expenditures ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December - 70300 % 0 % -50 %
3rd Quarter September - 800 % -75 % -55.56 %
2nd Quarter June - - - -96 %
1st Quarter March - 100 % 200 % -96.67 %
FY   - 14540 % -37.5 % -91.21 %

Financial Statements
X4 Pharmaceuticals Inc's first quarter 2025 Capital Expenditures $ 0.00 millions XFOR's Income Statement
X4 Pharmaceuticals Inc's first quarter 2024 Capital Expenditures $ 0.06 millions Quarterly XFOR's Income Statement


XFOR Capital Expenditures (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - 7722.22 % 0 % -75 %
3rd Quarter September - -30.77 % - 100 %
2nd Quarter June - 116.67 % - 100 %
1st Quarter March - 500 % 200 % -50 %
FY (Year on Year)   - 14540 % -37.5 % -91.21 %


Suppliers by XFOR Divisions >> Back to XFOR Growth rate Comparisons >>


Capital Expenditures first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #7
Healthcare Sector #58
Overall #387

Capital Expenditures Y/Y Growth Statistics
High Average Low
89.56 % -33.01 % -93.26 %
(Jun 30 2021)   (Jun 30 2022)
Capital Expenditures first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #7
Healthcare Sector #58
Overall #387
Capital Expenditures Y/Y Growth Statistics
High Average Low
89.56 % -33.01 % -93.26 %
(Jun 30 2021)   (Jun 30 2022)

Capital Expenditures by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

X4 Pharmaceuticals Inc's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


XFOR's I. Quarter Q/Q Capital Expenditures Comment
Recent accomplishment of 0.00 millions by X4 Pharmaceuticals Inc come out even worse considering the 7.04 millions a quarter before.

Within Biotechnology & Pharmaceuticals industry X4 Pharmaceuticals Inc achieved highest sequential Capital Expenditures growth. While X4 Pharmaceuticals Inc's Capital Expenditures growth quarter on quarter, overall rank is .


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Capital Expenditures Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


XFOR's I. Quarter Q/Q Capital Expenditures Comment
Recent accomplishment of 0.00 millions by X4 Pharmaceuticals Inc come out even worse considering the 7.04 millions a quarter before.

Within Biotechnology & Pharmaceuticals industry X4 Pharmaceuticals Inc achieved highest sequential Capital Expenditures growth. While X4 Pharmaceuticals Inc's Capital Expenditures growth quarter on quarter, overall rank is .


X4 Pharmaceuticals Inc's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Mar 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)
Cumulative Capital Expenditures 12 Months Ending $ 0.00 $ 7.33 $ 0.29 $ 0.21 $ 0.00
Y / Y Capital Expenditures Growth (TTM) - - - - -
Year on Year Capital Expenditures Growth Overall Ranking # # # # #
Seqeuential Capital Expenditures Change (TTM) - 2400.34 % 40.19 % - -
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 387 # 465 # 456 # 0 # 347


Cumulative Capital Expenditures growth Comment
In the Mar 31 2025 period, X4 Pharmaceuticals Inc's cumulative trailing twelve month Capital Expenditures remained unchanged compare to the same period a year ago.

X4 Pharmaceuticals Inc achieved highest trailing twelve month year on year Capital Expenditures growth. While overall Capital Expenditures growth ranking, remained unchanged compare to the previous quarter at no. .

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 7
Sector # 58
S&P 500 # 387
Cumulative Capital Expenditures growth Comment
In the Mar 31 2025 period, X4 Pharmaceuticals Inc's cumulative trailing twelve month Capital Expenditures remained unchanged compare to the same period a year ago.

X4 Pharmaceuticals Inc achieved highest trailing twelve month year on year Capital Expenditures growth. While overall Capital Expenditures growth ranking, remained unchanged compare to the previous quarter at no. .


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 7
Sector # 58
S&P 500 # 387




Other Capital Expenditures Growth
Biotechnology & Pharmaceuticals Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
XFOR's Capital Expenditures Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for XFOR's Competitors
Capital Expenditures Growth for X4 Pharmaceuticals Inc's Suppliers
Capital Expenditures Growth for XFOR's Customers

You may also want to know
XFOR's Annual Growth Rates XFOR's Profitability Ratios XFOR's Asset Turnover Ratio XFOR's Dividend Growth
XFOR's Roe XFOR's Valuation Ratios XFOR's Financial Strength Ratios XFOR's Dividend Payout Ratio
XFOR's Roa XFOR's Inventory Turnover Ratio XFOR's Growth Rates XFOR's Dividend Comparisons



Companies with similar Capital Expenditures meltdown for the quarter ending Mar 31 2025 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Mar 31 2025
Select Medical Holdings Corp-0.34%$ -0.339 millions
Si bone inc -0.48%$ -0.480 millions
Vaxart Inc -0.76%$ -0.763 millions
Mettler Toledo International Inc-0.78%$ -0.782 millions
Idexx Laboratories Inc-0.82%$ -0.816 millions
Gilead Sciences Inc -0.95%$ -0.952 millions
Johnson and Johnson-1.49%$ -1.487 millions
Iqvia Holdings Inc -2.07%$ -2.069 millions
Cadre Holdings inc -2.53%$ -2.532 millions
Myriad Genetics Inc -3.49%$ -3.488 millions
Irhythm Technologies Inc -3.65%$ -3.652 millions
Becton Dickinson And Company-3.73%$ -3.731 millions
Msa Safety Inc-3.88%$ -3.877 millions
Neurocrine Biosciences Inc -4.46%$ -4.464 millions
Vaxcyte Inc -4.47%$ -4.473 millions
Harvard Bioscience Inc -5.14%$ -5.139 millions
Procept Biorobotics Corporation-5.65%$ -5.653 millions
Labcorp Holdings Inc -5.83%$ -5.830 millions
Crinetics Pharmaceuticals Inc -6.98%$ -6.982 millions
Microbot Medical Inc -7.14%$ -7.143 millions
Maravai Lifesciences Holdings Inc -7.59%$ -7.590 millions
Amneal Pharmaceuticals Inc -8.13%$ -8.128 millions
Bristol myers Squibb Company-8.45%$ -8.451 millions
Community Health Systems Inc -8.60%$ -8.602 millions
Organon and Co -9.38%$ -9.375 millions
Treace Medical Concepts Inc -9.78%$ -9.778 millions
Novocure Limited-9.95%$ -9.954 millions
Revvity Inc-10.43%$ -10.435 millions
Icu Medical Inc-10.68%$ -10.684 millions
Carlisle Companies Incorporated-10.77%$ -10.769 millions


Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com